Johnson & Johnson (NYSE:JNJ) Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 570,448 shares of the company's stock after acquiring an additional 5,694 shares during the quarter. Calamos Advisors LLC's holdings in Johnson & Johnson were worth $94,603,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after acquiring an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC boosted its position in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after purchasing an additional 1,561,036 shares during the last quarter. Northern Trust Corp boosted its position in Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter worth about $4,390,037,000. Finally, Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 1.8% during the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock valued at $3,522,447,000 after buying an additional 431,205 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James Financial reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Barclays cut their target price on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Stock Up 0.5%

Shares of JNJ traded up $0.81 during trading hours on Tuesday, hitting $156.08. The company had a trading volume of 2,074,673 shares, compared to its average volume of 8,029,961. The company has a market capitalization of $375.54 billion, a PE ratio of 17.36, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company's fifty day moving average price is $153.67 and its two-hundred day moving average price is $154.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.33%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.